Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Patrick G. Enright sold 352 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the transaction, the director now directly owns 1,365 shares of the company’s stock, valued at $181,804.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded up $1.21 during trading hours on Wednesday, reaching $138.40. The company’s stock had a trading volume of 210,425 shares, compared to its average volume of 513,874. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. The stock has a market cap of $8,220.00, a PE ratio of 17.10, a P/E/G ratio of 0.81 and a beta of 1.00. Jazz Pharmaceuticals PLC has a 12 month low of $99.28 and a 12 month high of $163.75.

TRADEMARK VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/22/jazz-pharmaceuticals-plc-jazz-director-patrick-g-enright-sells-352-shares-of-stock.html.

A number of research analysts have issued reports on the company. Wells Fargo & Company reissued an “outperform” rating and issued a $177.00 price target (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. Cowen and Company reissued an “outperform” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Piper Jaffray Companies restated a “buy” rating and issued a $177.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Janney Montgomery Scott restated a “buy” rating and issued a $192.00 price objective (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Finally, BMO Capital Markets restated a “buy” rating and issued a $196.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have issued a buy rating to the stock. Jazz Pharmaceuticals PLC presently has a consensus rating of “Buy” and an average price target of $180.13.

Large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals PLC by 49.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 229,898 shares of the specialty pharmaceutical company’s stock valued at $35,750,000 after buying an additional 75,703 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Jazz Pharmaceuticals PLC by 41.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after buying an additional 410,031 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new stake in Jazz Pharmaceuticals PLC in the 2nd quarter valued at $10,108,000. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in Jazz Pharmaceuticals PLC by 13.8% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 17,469 shares of the specialty pharmaceutical company’s stock valued at $2,716,000 after buying an additional 2,121 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Jazz Pharmaceuticals PLC by 11,990.7% in the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after buying an additional 866,691 shares in the last quarter. Institutional investors own 90.52% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.